[Antigenicity tests of suplatast tosilate (IPD-1151T)].

[Mutagenicity tests of suplatast tosilate (IPD-1151T)].

Four new polymorphic forms of suplatast tosilate.

[Single dose toxicity studies of suplatast tosilate (IPD-1151T)].

Novel antitussive effect of suplatast tosilate in guinea pigs.

[Effect of suplatast tosilate (IPD-1151T) on types I-IV allergic reactions].

[Effects of suplatast tosilate (IPD-1151T) on antibody formations in mice].

[A fifty-two week oral chronic toxicity study of suplatast tosilate (IPD-1151T) in rats].

[A thirteen-week oral repeated dose toxicity study of suplatast tosilate (IPD-1151T) in dogs].

[A thirteen-week oral repeated dose toxicity study of suplatast tosilate (IPD-1151T) in rats].

[Reproductive and developmental toxicity study of suplatast tosilate (IPD-1151T) (2)--Teratological study in rats by oral administration].

[Reproductive and developmental toxicity study of suplatast tosilate (IPD-1151T) (4)--Perinatal and postnatal study in rats by oral administration].

Treatment of non-episodic angioedema associated with eosinophilia with suplatast tosilate, an anti-allergic selective Th2 cytokine inhibitor.

[Reproductive and developmental toxicity study of suplatast tosilate (IPD-1151T) (3)--Teratological study in rabbits by oral administration].

Protein antigenicity.

The antigenicity of chondrocytes.

Antigenicity of venous allografts.

Antigenicity of cryopreserved corneas.

Antigenicity of bdellovibrios.

Antigenicity of casein enzymatic hydrolysate.

Antigenicity of Helicobacter pylori lipopolysaccharides.

Antigenicity of rabies virus glycoprotein.

Antigenicity of methylated deoxyribonucleic acid.

Altering the antigenicity of proteins.

Fy3 antigenicity of blood of newborns.

Suggest Documents

[Mutagenicity tests of suplatast tosilate (IPD-1151T)].

Four new polymorphic forms of suplatast tosilate.

[Single dose toxicity studies of suplatast tosilate (IPD-1151T)].

Novel antitussive effect of suplatast tosilate in guinea pigs.

[Effect of suplatast tosilate (IPD-1151T) on types I-IV allergic reactions].

[Effects of suplatast tosilate (IPD-1151T) on antibody formations in mice].

[A fifty-two week oral chronic toxicity study of suplatast tosilate (IPD-1151T) in rats].

[A thirteen-week oral repeated dose toxicity study of suplatast tosilate (IPD-1151T) in dogs].

[A thirteen-week oral repeated dose toxicity study of suplatast tosilate (IPD-1151T) in rats].

[Reproductive and developmental toxicity study of suplatast tosilate (IPD-1151T) (2)--Teratological study in rats by oral administration].

[Reproductive and developmental toxicity study of suplatast tosilate (IPD-1151T) (4)--Perinatal and postnatal study in rats by oral administration].

Treatment of non-episodic angioedema associated with eosinophilia with suplatast tosilate, an anti-allergic selective Th2 cytokine inhibitor.

[Reproductive and developmental toxicity study of suplatast tosilate (IPD-1151T) (3)--Teratological study in rabbits by oral administration].

Protein antigenicity.

The antigenicity of chondrocytes.

Antigenicity of venous allografts.

Antigenicity of cryopreserved corneas.

Antigenicity of bdellovibrios.

Antigenicity of casein enzymatic hydrolysate.

Antigenicity of Helicobacter pylori lipopolysaccharides.

Antigenicity of rabies virus glycoprotein.

Antigenicity of methylated deoxyribonucleic acid.

Altering the antigenicity of proteins.

Fy3 antigenicity of blood of newborns.

[Antigenicity tests of suplatast tosilate (IPD-1151T)].

Recommend Documents

Follow Us